{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.86","upperLimit":"4.44","value":"3.78"},{"groupId":"OG001","lowerLimit":"2.96","upperLimit":"15.61","value":"4.40"}]}],"title":"Loss of appetite"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.63","upperLimit":"5.29","value":"3.06"},{"groupId":"OG001","lowerLimit":"2.43","upperLimit":"3.98","value":"3.09"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.21","upperLimit":"7.82","value":"6.05"},{"groupId":"OG001","lowerLimit":"3.06","upperLimit":"15.61","value":"4.67"}]}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.21","upperLimit":"10.87","value":"5.36"},{"groupId":"OG001","lowerLimit":"2.83","upperLimit":"15.61","value":"4.40"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"comment":"Median (95% confidence interval) TWS for hemoptysis was not calculated due to the high level of censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median (95% confidence interval) TWS for hemoptysis was not calculated due to the high level of censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.57","upperLimit":"9.56","value":"6.11"},{"groupId":"OG001","lowerLimit":"3.32","upperLimit":"5.98","value":"4.63"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.58","upperLimit":"5.55","value":"4.21"},{"groupId":"OG001","lowerLimit":"2.99","upperLimit":"18.53","value":"3.78"}]}],"title":"Symptomatic distress"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.34","upperLimit":"8.18","value":"6.51"},{"groupId":"OG001","lowerLimit":"2.83","upperLimit":"15.61","value":"3.98"}]}],"title":"Interference with activity level"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.37","upperLimit":"8.41","value":"5.75"},{"groupId":"OG001","lowerLimit":"2.99","upperLimit":"5.49","value":"3.71"}]}],"title":"Global quality of life"}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"TWS was the elapsed time from the date of randomization to the first date of worsening \\[defined as a 15-millimeter (mm) increase from baseline based on a 100-mm scale\\] of each symptom and summary item in the Lung Cancer Symptom Scale (LCSS). The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant (pt) responses to each item were measured using visual analogue scales (VAS) from 0 (for best outcome) to 100 (for worst outcome). TWS was censored at the date of the last LCSS assessment for pts who were not known to have LCSS worsening.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"MEDIAN","populationDescription":"Pts who signed ICF and completed randomization, according to treatment randomized. Pts censored: Loss of appetite 236,140; fatigue 237,130; cough 274,146; dyspnea 271,143, hemoptysis 404,198; pain 271,135; symptom distress 247,141; interference with activity level 267,141, global quality of life 262,137 pts in pemetrexed, placebo arm, respectively.","reportingStatus":"POSTED","timeFrame":"Randomization to worsening of each LCSS item (up to 39 months)","title":"Time to Worsening of Symptoms (TWS)","type":"SECONDARY","unitOfMeasure":"months"}